Tasly disclosed its 2026 half-year report, with net profit attributable to the parent up 15.23% year on year. During the reporting period, the company achieved total operating revenue of 4.201 billion yuan, net profit attributable to shareholders of the listed company of 893 million yuan, and non-GAAP net profit of 870 million yuan, up 36.00% year on year. A total of 10 of the company's products were newly included in the National Essential Medicines List, 2026 edition, including two exclusive products, Jinghua Weikang Capsules and Shaoma Zhijing Granules. A research report from Guosheng Securities noted that the company fully released earnings elasticity in the second quarter, and the sharp growth in non-GAAP net profit verified the effectiveness of cost reduction and efficiency improvement. The inclusion of ten products in the new edition of the essential medicines list will continue to open up incremental markets at the primary-care level.
Tasly Pharmaceutical Group Co LtdNet profit attributable to parent up 15.23% and non-GAAP net profit up 36% in H1 2026.
Guosheng Financial Holding Inc